NovoCure Limited (NASDAQ:NVCR) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET
Company Participants
Ingrid Goldberg - IR
Bill Doyle - Chairman
Ashley Cordova - CFO
Asaf Danziger - CEO
Frank Leonard - EVP and President of NovoCure Oncology
Nicolas Leupin - Chief Medical Officer
Conference Call Participants
Jason Bednar - Piper Sandler
Jonathan Chang - Leerink Partners
Emily Bodnar - H.C. Wainwright
Jessica Fye - JPMorgan
Operator
Good day, and thank you for standing by. Welcome to the NovoCure Q3 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Ingrid Goldberg. Please go ahead.
Ingrid Goldberg
Good morning, and thank you for joining us to review NovoCure’s third quarter 2024 performance. I am on the phone this morning with our Executive Chairman, Bill Doyle, our CEO, Asaf Danziger, and our CFO, Ashley Cordova. Other members of our executive leadership team will be available for Q&A. For your reference, slides accompanying this earnings release can be found on our website, www.novocure.com, on the investor relations page under quarterly reports.
Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements, and actual results could differ materially from those projected in these statements. These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings. We do not intend to update publicly any forward-looking statement, except as required by law.
Where appropriate, we refer to non-GAAP financial measures to evaluate our business, specifically adjusted EBITDA, a measure of earnings before interest, taxes, depreciation, amortization, and share-based compensation. We believe adjusted EBITDA is an important metric as it removes the impact of earnings attributable to our capital structure, tax rate, and material non-cash items, and best reflects the financial value generated by our business. Reconciliations of non-GAAP to GAAP financial measures are included in our press release, earnings slides, and in our Form 8-K filed with the SEC today. These materials can also be accessed from the investor relations page of our website. Following our prepared remarks today, we will open the line for your questions.
I will now turn the call over to our Executive Chairman, Bill Doyle.